Jens Bager
Chairman
Education: MSc in Economics and Business Administration from Copenhagen Business School
Past and present: Since 2016 Jens Bager has focused on non-executive directorships and has been Chairman of a number of companies including Ambu A/S and the Grundfos Foundation. He currently serves as Chairman for Better Collective A/S, Scantox A/S and Marleybones Ltd. Other assignments include member of the executive board of Apto Invest ApS, Apto Advisory ApS, Tandlagen.dk and Symmetry Administration ApS.
Chairman of the board since: 2021
Nicholas Hooge
Education: MSc in business administration and management science from Copenhagen Business School
Past and present: Nicholas joined Impilo as partner in 2020 and is a member of Impilo’s investment committee. Prior to this he was a Senior Director at EQT Partners where he worked from 2006-2019, based both in Copenhagen and New York with a focus on private equity and Infrastructure investments. From 2004-2006 Nicholas worked for Deutsche Bank in London focusing on M&A in the Nordic countries.
Member of the board since: 2021
Daniel Spasic
Education: Technical degree in chemical engineering and an OPM from Harvard Business School.
Past and present: Daniel has close to 30 years in senior life science executive roles. In 1996 he joined Pharmacia & Upjohn in clinical drug development. He later founded TFS Health Sciences, a global clinical Contract Research Organization. His expertise covers biopharma services and research technology-enabled services. He is currently serving as Executive Chairman in Julius Clinical, iuvo Biosciences and Inhalation Sciences and board NED in Scantox, Avance Clinical, Trialbee and PathoQuest. Daniel is based in Boston, USA.
Member of the board since: 2021
Karsten Lindhardt
Education: MSc and PhD in pharmacology and biopharmacy from Danmarks Farmaceutiske Universitet. Diploma from CBS Copenhagen Business School
Past and present: Karsten Lindhardt is the Founder and CEO of Biograil; a company that specializes in developing oral delivery systems for biologics. Prior to Biograil, Lindhardt served as the Chief Scientific Officer at Egalet Corporation [EGLT] NASDAQ NY . He has previously worked at Novo Nordisk, Ferring Pharmaceuticals, OSI Pharmaceuticals and Curalogic. He has co-founded various start-up companies and serves in the research grant evaluation panel in Growth Fund Denmark
Member of the board since: 2021
Mette K. Agger
Education: MSc in Biology and an MBA.
Past and present: Senior Advisor and board member for numerous biopharma companies, where she utilizes her extensive industry experience as a strategic advisor. Currently serves on several boards, including KLIFO, ScPharmaceuticals, D.O.F. and C. V Obel A/S. Previously a managing partner of Lundbeckfonden Ventures, and later Senior Advisor for Lundbeckfonden BioCapital (succeeding Lundbeckfonden Ventures). Earlier on, CEO and co-founder of 7TM Pharma A/S, and part of the management team of NeuroSearch A/S.
Member of the board since: 2024
Mark Treherne
Education: B.Sc. Physiology and Pharmacology, University of St Andrews. MPhil and PhD in Pharmacology, University of Cambridge
Past and present: Commercial research scientist with 30 years’ experience in developing novel treatments. Formerly at Pfizer and responsible for research into neurodegenerative diseases in the UK. Subsequently, set up Cambridge Drug Discovery as a co-founder and Chief Executive, which was sold to BioFocus and then to Charles River. Now serves on the boards of multiple therapeutics, research services, research tools and diagnostics companies worldwide.
Member of the board since: 2024
Impilo
Scantox is owned by the Nordic based investment company Impilo. Impilo is focused solely on investments in Nordic companies operating in the pharmaceutical, medical technology, healthcare services and other health-related industries. Their starting point is that their portfolio companies must contribute to a positive and sustainable development of the communities and markets in which they operate in order to remain successful in the long term. Impilo invests in people’s opportunities to enjoy healthier lives in the future.
